Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review

Laura Drikite1*, Jonathan P. Bedford1, Liam O’Bryan1, Tatjana Petrinic4, Kim Rajappan6, James Doig2, David A. Harrison2, Kathryn M. Rowan2, Paul R. Mouncey2, Duncan Young1, Peter J. Watkinson3 and Mark Corbett5

Abstract

Background: New-onset atrial fibrillation (NOAF) in patients treated on an intensive care unit (ICU) is common and associated with significant morbidity and mortality. We undertook a systematic scoping review to summarise comparative evidence to inform NOAF management for patients admitted to ICU.

Methods: We searched MEDLINE, EMBASE, CINAHL, Web of Science, OpenGrey, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, ISRCTN, ClinicalTrials.gov, EU Clinical Trials register, additional WHO ICTRP trial databases, and NIHR Clinical Trials Gateway in March 2019. We included studies evaluating treatment or prevention strategies for NOAF or acute anticoagulation in general medical, surgical or mixed adult ICUs. We extracted study details, population characteristics, intervention and comparator(s), methods addressing confounding, results, and recommendations for future research onto study-specific forms.

Results: Of 3,651 citations, 42 articles were eligible: 25 primary studies, 12 review articles and 5 surveys/opinion papers. Definitions of NOAF varied between NOAF lasting 30 s to NOAF lasting > 24 h. Only one comparative study investigated effects of anticoagulation. Evidence from small RCTs suggests calcium channel blockers (CCBs) result in slower rhythm control than beta blockers (1 study), and more cardiovascular instability than amiodarone (1 study). Evidence from 4 non-randomised studies suggests beta blocker and amiodarone therapy may be equivalent in respect to rhythm control. Beta blockers may be associated with improved survival compared to amiodarone, CCBs, and digoxin, though supporting evidence is subject to confounding. Currently, the limited evidence does not support therapeutic anticoagulation during ICU admission.

Conclusions: From the limited evidence available beta blockers or amiodarone may be superior to CCBs as first line therapy in undifferentiated patients in ICU. The little evidence available does not support therapeutic anticoagulation for NOAF whilst patients are critically ill. Consensus definitions for NOAF, rate and rhythm control are needed.

Keywords: New onset atrial fibrillation, Intensive care, Critical care, Scoping review, Arrhythmia, Stroke

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

New onset atrial fibrillation (NOAF), usually defined as atrial fibrillation (AF) occurring in patients with no known history of AF [1], is a common arrhythmia in critically ill patients [2]. NOAF occurs in 5–11% of patients...
admitted to an intensive care unit (ICU) [3–6], and up to 46% of patients with septic shock [7, 8]. NOAF in critically ill patients can cause cardiovascular instability [5] and is associated with increased risk of thromboembolism [9], increased mortality [10] and length of ICU stay [11], and higher healthcare costs [11].

Guidelines for management of AF [12, 13] do not directly apply to critically ill patients. NOAF in patients treated on an ICU differs from AF in patients in the community in terms of causes of rhythm disturbance [14, 15], risks and effectiveness of treatments [16]. The lack of evidence for managing NOAF in patients treated on an ICU means treatment practice differs widely [17].

We conducted a scoping review to provide an overview of current evidence for the effectiveness and safety of pharmacological, electrical, and other non-pharmacological NOAF treatments, prophylactic strategies, and acute anticoagulation for stroke prophylaxis in critically ill patients. We also aimed to describe commonly used definitions of NOAF in patients treated on an ICU and suggest recommendations and barriers for future research.

A recent scoping review described the incidence, risk factors, outcomes and management strategies related to NOAF during critical illness [10]. It included patients with pre-existing AF and studies conducted outside ICUs. Our review focusses on the comparative evidence for treatment of NOAF in patients treated on an ICU.

Materials and methods

Search and identification of studies

We developed our search strategy with an information specialist (TP) in MEDLINE with no date or language restrictions. We included terms used for NOAF combined with terms used for intensive care (see Additional file 1).

We adapted the MEDLINE search strategy to identify papers in the following databases in March 2019: MEDLINE, EMBASE, CINAHL, Web of Science (including Conference Proceedings Citation Index: Science), OpenGrey, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Database of Abstracts of Reviews of Effects (DARE) to 2015. The following clinical trial databases were searched for studies in progress, or completed but not reported: ISRCTN, ClinicalTrials.gov, the EU Clinical Trials register, additional WHO ICTRP trial databases, and the NIHR Clinical Trials Gateway.

Eligibility criteria

We included studies of adults (age ≥ 16 years) in general medical, surgical or mixed ICUs. We excluded studies of cohorts defined by a single disease or narrow disease group not normally admitted to a general ICU, and studies based on service-specific ICUs. We included studies of pharmacological, electrical and other non-pharmacological treatment strategies for treatment or prophylaxis of NOAF and the use of acute anticoagulation. The outcomes of interest were rhythm and rate control, length of ICU and hospital stay, mortality (ICU, hospital, 30-day, long term), arterial thromboembolism and adverse treatment effects. Quantitative studies, reviews, practitioner surveys, and opinion pieces were eligible for this review.

Study selection and data charting

We used EPPI-Reviewer 4 software (Evidence for Policy and Practice Information and Co-ordinating Centre, University of London, London, UK) to identify duplicate records and for title and abstract screening. Two reviewers (LD and LOB) independently screened titles, abstracts and full-text articles, with discrepancies resolved through discussion or by a third reviewer (MC).

We also reviewed reference lists of included studies for further relevant citations. Full-text articles not published in English were screened by native speakers.

We developed data charting forms (see Additional file 1: Tables S1–S10) for the following study designs: randomised controlled trials (RCTs), prospective comparative studies, retrospective comparative studies, and non-comparative studies. The extracted data included: details of the study, population characteristics, description of intervention and comparator(s), methods to address confounding, results, and recommendations for future research.

Decisions about which population characteristics to extract were informed by a systematic review on risk factors for NOAF on the ICU [18] and a retrospective observational study on predictors for sustained NOAF in the critically ill [19]. Data were extracted by one reviewer (LD) and checked by another (JB); disagreements were referred to a third reviewer (MC).

Critical appraisal

We evaluated RCTs using version 2 of the Cochrane risk of bias tool [20]. We evaluated non-randomised comparative studies for risk of bias using the ROBINS-I tool [21] if they were reported as full papers, included at least 100 patients per treatment arm and reported on methods to adjust for confounding.

Studies which did not meet these criteria were deemed to be at a critical risk of bias. The ROBINS-I tool was adapted by including a stopping rule: the assessment stopped if a serious, or critical, risk of bias judgement was made for the ‘bias due to confounding’ domain. For the confounding domain, decisions regarding which covariates should be reported as being controlled for in
analyses were made by the clinical experts in the CAFE study team and are reported in Additional file 1 along with the risk of bias judgements (see Additional file 1: Tables S11).

**Collating and summarising results**
We presented details of the primary studies in structured tables categorised by pairwise drug comparison and by study design. For each type of study design, we described the extent, range and nature of the identified research. Study parameters and results were then described and summarised narratively.

**Results**

**Search results**
Of the 3651 articles screened on title and abstract, 198 articles were identified as being of potential interest and screened on full text. After full text screening, 42 articles were included in the review: 25 primary studies, 12 review articles and 5 surveys/opinion papers. Of the 25 primary studies, two RCTs [22, 23] two prospective comparative studies [24, 25], nine retrospective comparative studies [26–34] and 12 non-comparative studies [5, 35–45] were included. Six studies [27–30, 32, 39] were available only as conference abstracts. Figure 1 illustrates the flow of the articles through the review process.

---

**Fig. 1** Flow chart showing the number of studies identified, excluded and eligible for inclusion in the scoping review.
Characteristics of included studies
Nine studies [22, 24, 27, 31, 35, 37, 41, 43, 44] were conducted in specialty ICUs such as surgical, trauma, or medical. Five studies [5, 23, 38, 42, 45] were conducted in mixed ICUs and one study [26] in a general ICU. The type of ICU was not specified in 10 studies [25, 28–30, 32–34, 36, 39, 40]. Eleven studies included patients with sepsis [5, 27, 28, 33–35, 38, 43] or septic shock [25, 26, 29] as primary diagnoses. Four studies [22, 24, 31, 41] were conducted in a noncardiac surgical population. Two studies included noncardiac and cardiac surgery patients [37, 44] and one study was conducted in surgical population; however, the type of surgery was not specified [40].

Nineteen studies [5, 22–24, 26–28, 30–33, 35, 36, 38, 40, 41, 43–45] investigated the treatment effects of pharmacological treatments, two studies [25, 29] looked at prophylactic treatments, and two studies [37, 42] investigated electrical treatments. One study [39] reported on both pharmacological treatments and anticoagulation for stroke prophylaxis. One study [34] on anticoagulation was included in the review.

Overview of the primary study evidence by intervention and study design can be found in Additional file 1: Tables S12.

Definitions used for NOAF
Studies varied in how they reported and defined NOAF. Five studies [5, 31, 35, 37, 44] defined NOAF as having AF with a heart rate of ≥100 beats per minute and two studies [23, 32] used a heart rate threshold of ≥120 beats per minute. Seven studies [22, 23, 25, 35, 37, 43, 44] reported different time periods for which NOAF must be sustained, ranging from 30 s to 24 h. Six studies [5, 31, 33, 34, 40, 42] specified in which instances AF would be considered as ‘new onset’. For example, when a patient had no prior history of AF [31], without previous history of atrial tachyarrhythmias and antiarrhythmic drug use [40], and AF not present on admission [33, 34]. Ten studies [24, 26–30, 36, 38, 39, 41] did not provide any definition for NOAF.

Results from comparative studies

**Amiodarone versus beta blockers**
Six retrospective comparative studies [26, 28, 30–33] compared amiodarone with beta blockers (Table 1, Additional file 1: Tables S5 and S6). Most studies did not report on doses [28, 31–33] or modes of administration [28, 31, 32]. A large study [33] of 39,693 patients with sepsis reported that patients treated with amiodarone were more likely to be critically ill with septic shock than patients treated with beta blockers. After adjustment for confounding, beta blockers were associated with lower mortality than amiodarone (RR 0.67, 95% CI: 0.59–0.77) [33]. However, only 60% of patients were on an ICU. Therefore, this study’s results may not be applicable to a broad ICU population. The study was also judged as being at a serious risk of bias due to confounding (Additional file 1). Balik et al. [26] showed higher but not statistically significant ICU mortality in patients receiving amiodarone (40%) than in patients receiving metoprolol (21%) [26]. A conference abstract by Jaffer et al. [28] also reported no statistically significant difference in mortality. Four studies [26, 30–32] compared conversion rates between amiodarone and beta-blockers. Three studies [26, 30, 32] showed no statistically significant difference in cardioversion rates between the treatments. Balik et al. [26] did not adjust for confounding factors such as illness severity [26]. Two studies did not report on the methods used for the analysis [30, 32]. No meaningful conclusions from the results of Brown et al. could be made with only 60 patients receiving amiodarone [31]. Figure 2 shows rhythm control risk ratio results for studies comparing amiodarone with beta blockers. Although Fig. 2 enables a crude comparison of results, the studies were too heterogeneous for this to depict a true comparison. It should also be noted that only studies which reported numerators and denominators for the rhythm control outcome could be included in Fig. 2.

**Amiodarone versus calcium channel blockers**
One RCT [23], one prospective [24] and three retrospective comparative studies [28, 31, 32] compared amiodarone and calcium channel blockers (Table 2, Additional file 1: Tables S1, S2, S3, S4, S5, and S6), all were relatively small with between eight and 61 patients included.

A small RCT of 60 patients compared diltiazem, amiodarone bolus and amiodarone bolus followed by an amiodarone infusion in a mixed ICU population [23]. No evidence of a difference was identified between treatment groups in the primary study endpoint of rate reduction ≥30% at 4 h. Hypotension resulting in drug discontinuation was more common with diltiazem use (30%) vs amiodarone (0–5%). This study [23] was judged to have a high risk of bias. A non-randomised study comparing diltiazem and amiodarone in a non-cardiac surgical ICU population found no evidence of differences between the study groups in the proportion cardioverted at 24 h or in time to cardioversion [24]. No evidence of a difference in rates of hypotension was identified. Similar length of ICU and hospital stays was also reported. This study [24] was small and most likely underpowered to detect any treatment differences. A conference abstract found no statistically significant difference in mortality at discharge [28]. Two studies [31, 32] compared rate and rhythm control between treatment groups but results were subject to
Table 1  Studies comparing amiodarone and beta blockers

| Authors                        | Sample size and setting | Primary diagnosis  | Study design and risk of bias | Intervention                                                                 | Rate control outcome | Rhythm control outcome | Mortality outcome |
|--------------------------------|-------------------------|--------------------|-------------------------------|-------------------------------------------------------------------------------|----------------------|------------------------|-------------------|
| Walkey et al. (2016)           | n = 3174* (NOAF patients) Setting: USA  | Sepsis             | Retrospective comparative Risk of bias: Serious | Beta blockers (metoprolol, esmolol, atenolol, labetalol, propranolol) versus amiodarone | Not assessed          | Not assessed           | Hospital RR 0.67 (95% CI 0.59–0.77) |
| Matsumoto et al. (2015) (conference abstract) | n = 276 n = 116 (amiodarone) n = 160 (landiolol) Setting: Japan ICU  | Not reported         | Retrospective comparative Risk of bias: Critical | Amiodarone versus landiolol | Not assessed          | NS^f                      | Not assessed       |
| Balk et al. (2017)             | n = 234^d n = 177 (amiodarone) n = 15 (metoprolol) Setting: Czech Republic general ICU  | Septic shock        | Retrospective comparative Risk of bias: Critical | Amiodarone versus metoprolol | Not assessed          | Amiodarone: 74% Metoprolol: 92% | ICU NS            |
| Mieure et al. (2011) (conference abstract) | n = 126^e n = 61 (amiodarone) n = 24 (metoprolol) Setting: USA ICU  | Not reported         | Retrospective comparative Risk of bias: Critical | Amiodarone versus metoprolol | < 100 bpm within 24 h from initiation of treatment: Amiodarone: 85.2% Metoprolol: 87.5% | p = 0.013 Amiodarone: 21.3% Metoprolol: 37.5% | Not assessed |
| Jaffer et al. (2016) (conference abstract) | n = 65 Setting: USA ICU  | Septic shock        | Retrospective comparative Risk of bias: Critical | Amiodarone versus beta blockers (drug not specified) | Not assessed          | Not assessed           | NS                |
| McKenzie Brown et al. (2018)   | n = 33^e n = 6 (amiodarone) n = 22 (beta blockers) Setting: USA surgical ICU  | Noncardiac surgical population | Retrospective comparative Risk of bias: critical | Amiodarone versus beta blockers (drug not specified) | p = 0.001 Amiodarone: 83% Beta blockers: 7% | p = 0.001 Amiodarone: 83% Beta blockers: 7%  | Not compared between treatment groups |

^ Includes calcium channel blockers and digoxin groups
^d Relative risk
^f Statistically not significant
^d Includes propafenone group
^e Includes calcium channel blockers and no treatment groups
much uncertainty due to the limited data reported [32] and small sample size [31]. Figure 2 shows rhythm control risk ratio results for studies comparing amiodarone with calcium channel blockers.

**Beta blockers versus calcium channel blockers**

One RCT [22] and three retrospective comparative studies [28, 31, 33] compared beta blockers with calcium channel blockers (Table 3, Additional file 1: Tables S1, S2, S5 and S6). Balser et al. [22] conducted a RCT \( (n=55) \) comparing esmolol with diltiazem in a noncardiac surgical population. Conversion to sinus rhythm was more common in the esmolol group at 2 h (59% vs 33%, \( p=0.049 \)); however there was no statistically significant difference at 12 h. There was also no evidence of a difference in hospital mortality [22]. This RCT was judged as having some concerns about possible bias primarily due to the lack of reporting of randomisation methods and the lack of blinding (Additional file 1). Another study [31] compared conversion rates in a surgical ICU population but the sample size was too small to make any conclusions. Two retrospective comparative studies [28, 33] reported no evidence of a difference in hospital mortality.

**Beta blockers versus digoxin**

One large retrospective study [33] investigated the outcomes in patients who received digoxin versus patients who received beta blockers (Additional file 1: Tables S5, S6, S13, and S4). Following propensity score matching (\( n=1932 \)), hospital mortality was lower in patients who received beta-blockers compared to patients who received digoxin (RR 0.75 (95% CI: 0.64–0.88)). The study was judged as being at a serious risk of bias due to confounding (Additional file 1).

**Hydrocortisone versus no treatment**

One prospective study [25] and one retrospective study [29] compared hydrocortisone as a prophylactic treatment with no treatment (Table 4, Additional file 1: Tables S3, S4, S5 and S6). Balser et al. (2019) reported that the unadjusted ICU and 28-day mortality in the hydrocortisone group was higher than when compared to the no treatment group (37% versus 24% (\( p=0.018 \)); and 38% versus 26% (\( p=0.036 \)), respectively), noting that patients who received hydrocortisone were more severely ill than those who did not receive hydrocortisone [25]. However, in the propensity score-weighted analysis, patients who received hydrocortisone were less likely to develop NOAF compared to patients who did not [risk difference 11.9%, RR 0.58 (95% CI 0.35–0.98)] [25]. This study [25] was judged to have serious risk of bias due to missing covariates in the propensity score matching. Similarly, the retrospective study [29] concluded that administering hydrocortisone was associated with a reduction in NOAF incidence. No evidence of a difference in mortality between the study groups was reported [29]. However, this study [29] was published as a conference abstract with limited data available and the dose of hydrocortisone was not reported [29].

**Anticoagulation versus no treatment**

Published comparative evidence for anticoagulation was very limited. One large retrospective study [34] found no benefit from in-hospital anticoagulation for NOAF in sepsis but was at high risk of bias (Additional file 1: Tables S5, S6 and S14). The study \( (n=38,582 \) with any AF, \( n=7522 \) with NOAF) [34] included hospitalised patients, around 60% of whom were treated on an ICU. Rates of in-hospital stroke were low in the NOAF cohort.
| Authors                  | Sample size and setting | Primary diagnosis                        | Study design and risk of bias | Intervention                                      | Rate control outcome | Rhythm control outcome | Mortality outcome |
|-------------------------|-------------------------|------------------------------------------|-------------------------------|--------------------------------------------------|----------------------|------------------------|-------------------|
| Delle Karth et al. (2001) | $n=60$ $n=20$ (diltiazem) $n=20$ (amiodarone bolus) $n=20$ (amiodarone bolus and 24 h infusion) Setting: Austria ICU | Mixed cardiac and medical ICU population | RCT\(^a\) Risk of bias: high | Diltiazem versus amiodarone bolus versus amiodarone bolus and 24 h continuous infusion | Rate reduction within 4 h: NS\(^b\) Diltiazem: 70% Amiodarone: 59% Amiodarone bolus with 24 h continuous infusion: 79% Rate reduction within 24 h: Diltiazem versus amiodarone groups $p=0.001$ Amiodarone bolus versus amiodarone bolus with 24 h continuous infusion: $p=0.08$ | Within 4 h: NS Diltiazem: 30% Amiodarone bolus: 40% Amiodarone bolus with 24 h continuous infusion: 45% | Not assessed |
| Gerlach et al. (2008)   | $n=61$ $n=55$ NOAF patients $n=28$ (diltiazem) $n=27$ (amiodarone) Setting: USA Surgical ICU | Noncardiac surgical population | Prospective comparative Risk of bias: Critical | Diltiazem versus amiodarone | Not assessed | At 24 h: NS Diltiazem: 87% Amiodarone: 87% Mean time to conversion: NS Diltiazem: 7 h Amiodarone: 5 h | Not assessed |
| Jaffer et al. (2016) (conference abstract) | $n=65$ Setting: USA ICU | Septic shock | Retrospective comparative Risk of bias: Critical | Calcium channel blockers (drug not specified) versus amiodarone | Not assessed | Not assessed | NS |
| Mieure et al. (2011) (conference abstract) | $n=126^c$ $n=61$ (amiodarone) $n=41$ (diltiazem) Setting: USA ICU | Not reported | Retrospective comparative Risk of bias: Critical | Diltiazem versus amiodarone | At 24 h: NS Diltiazem: 85% Amiodarone: 85% | Diltiazem: 7% Amiodarone: 21% | Not assessed |
| McKenzie Brown et al. (2018) | $n=33^d$ $n=6$ (amiodarone) $n=2$ (calcium channel blockers) Setting: USA Surgical ICU | Noncardiac surgical population | Retrospective comparative Risk of bias: Critical | Calcium channel blockers (drug not specified) versus amiodarone | Amiodarone: 83% Calcium channel blockers: 50% | Amiodarone: 83% Calcium channel blockers: 50% | Not assessed |

\(^a\) Randomised controlled trial
\(^b\) Statistically not significant
\(^c\) Includes beta blockers group
\(^d\) Includes beta blockers group no treatment groups
| Authors                          | Sample size and setting | Primary diagnosis          | Study design and risk of bias | Intervention | Rate control outcome | Rhythm control outcome | Mortality outcome |
|---------------------------------|-------------------------|----------------------------|-------------------------------|--------------|----------------------|------------------------|--------------------|
| Balser et al. (1998)            | \(n = 55\)              | Noncardiac surgical population | RCT\(^a\) Risk of bias: Some concerns | Esmolol versus diltiazem | Not assessed         | Within 2 h: NS\(^b\) Esmolol: 59% Diltiazem: 27% | Hospital: NS Esmolol: 31% Diltiazem: 38% |
| Walkey et al. (2016)            | \(n = 3,174^c\) (NOAF patients) | Sepsis | Retrospective comparative Risk of bias: Serious | Beta blockers (metoprolol, esmolol, atenolol, labetalol, propranolol) versus calcium channel blockers (diltiazem, verapamil) | Not assessed         | Not assessed         | Hospital: RR\(^d\) 0.99 (95% CI: 0.86–1.15) |
| Jaffer et al. (2016)            | \(n = 65\)              | Septic shock | Retrospective comparative Risk of bias: Critical | Beta blockers versus calcium channel blockers (drugs not specified) | Not assessed         | Not assessed         | NS                  |
| McKenzie Brown et al. (2018)    | \(n = 33^e\)            | Noncardiac surgical population | Retrospective comparative Risk of bias: critical | Beta blockers versus calcium channel blockers (drugs not specified) | Beta blockers: 27% Calcium channel blockers: 50% | Beta blockers: 27% Calcium channel blockers: 50% | Not assessed |

---

\(^a\) Randomised controlled trial

\(^b\) Statistically not significant

\(^c\) Includes amiodarone and digoxin groups

\(^d\) Relative risk

\(^e\) Includes amiodarone group and no treatment groups
(1.9%). As the hospital length of stay was not reported, the duration of exposure was unclear [34]. Following propensity score matching ($n = 5585$ analysed), rates of in-hospital ischaemic stroke events and risk of bleeding did not differ significantly between patients who did, and did not, receive parenteral anticoagulation. Given the low event rate, the study [34] may have had inadequate power to determine whether a significant difference exists.

**Results from non-comparative studies**

The following pharmacological treatments were investigated in non-comparative studies: amiodarone [5, 39, 41, 43–45], magnesium-amiodarone step-up scheme [40], beta-blockers [5, 38, 41, 43], calcium channel blockers [5, 41, 43], digoxin [5, 41, 43], and ibutilide [35, 36]. Two non-comparative studies looked at electrical treatments [37, 42].

Two studies investigated anticoagulant therapy. One study reported a 5% risk of major bleeding with IV heparin, though thromboembolism events were not reported [39]. Another study reported a 9% (5/58) risk of major bleeding with therapeutic anticoagulation in patients with NOAF and pre-existing AF [5] with no strokes occurring during ICU admission.

Details of non-comparative studies are reported in Additional file 1: Tables S7, S8, S9 and S10.

**Results from review articles, surveys, and opinion pieces**

A full summary of the reviews, surveys and opinion pieces identified in the review is reported in Additional file 1.

**Reported recommendations for future research**

Most studies and review articles that were included in this review concluded that further prospective research accounting for confounding factors is required to determine the success and clinical implications of prophylactic and treatment strategies in patients treated in an ICU with NOAF [5, 6, 14, 22, 24, 25, 28, 29, 32, 33, 38, 40, 41, 43, 46–52]. It was emphasised that optimal regimens and best dosing strategies for treatments are yet to be established [31, 37, 45]. Eight studies [23, 26, 27, 30, 35, 36, 39, 44] and four review articles [53–56] did not provide any recommendations for future research.

**Discussion**

The evidence base for NOAF management for patients in ICU was limited. Many studies identified in this scoping review were non-comparative studies (i.e. lacking a comparator group, $n = 12$). Of the 25 primary studies included in the review only two were RCTs [22, 23] and only three of the non-randomised comparative studies [25, 33, 34] attempted to control for confounding factors. In the studies which used more robust approaches, there were nevertheless still concerns about how bias (arising from their designs and/or analyses) might affect their results. Moreover, considerable heterogeneity defining NOAF, treatment doses (e.g. total dose ranging from less than a gram to eight grams for amiodarone) [5, 23, 24, 26, 30, 44, 45], administration (e.g. bolus or continuous infusion), and timepoints to assess conversion to sinus rhythm (e.g. within two [22], four [23], 12 [23], and 24 h [5, 24, 26, 32] was observed across studies. Similarly, a systematic review was not able to make evidence-based recommendations for pharmacologic rhythm conversion strategies for patients who develop NOAF in a general ICU due to considerable methodological heterogeneity of the included studies [48]. There is therefore a need to establish optimal treatment dosing and administration

### Table 4: Studies comparing hydrocortisone and no treatment

| Authors                  | Sample size and setting | Primary diagnosis | Study design and risk of bias | Intervention | Incidence of NOAF | Mortality outcome |
|--------------------------|-------------------------|-------------------|-------------------------------|--------------|-------------------|------------------|
| Launey et al. (2019)     | $n = 261$ $n = 123$ (hydrocortisone) $n = 138$ (no treatment) Setting: France ICU | Septic shock | Prospective comparative Risk of bias: serious | Hydrocortisone vs no treatment | RD: $11.9\%$ (95% CI: $-23.4\%$ to $-0.5\%$) RR: $0.58$ (95% CI: $0.35$ to $0.98$) | ICU: NS Hydrocortisone: $37\%$ No treatment: $24\%$ 28-day: NS Hydrocortisone: $38\%$ No treatment: $26\%$ |
| Kane and Hanes (2014) (conference abstract) | $n = 109$ $n = 39$ (hydrocortisone) Setting: USA ICU | Septic shock | Retrospective comparative Risk of bias: critical | Hydrocortisone vs no treatment | $p = 0.006$ Hydrocortisone: $20.5\%$ No treatment: $42.9\%$ | NS |

Risk difference

Relative risk

Statistically not significant
regimens, as well as standardised and validated outcome measures of treatment success.

The limited evidence from this review [26, 30, 32] suggests that beta-blockers may be equivalent to amiodarone for rhythm control. Where reduced mortality in those who received beta-blockers compared to those who received amiodarone was reported [26, 33], there were significant concerns about bias. Despite this, some review articles [46, 50, 51] argued that beta blockers may be a reasonable first-choice treatment due to the current evidence of decreased mortality [46], and improved heart rate control [46, 50]. Two opinion pieces [14, 57] also favoured the use of beta-blockers as the initial pharmacotherapy, given the limited and indirect evidence. In contrast, five reviews discussed amiodarone as a potentially effective treatment [47, 49, 52–54], though it was also recognised that amiodarone has potentially significant side effects [47, 52, 54].

Calcium channel blockers appeared to be less effective for conversion to sinus rhythm when compared with beta blockers, and result in more hypotension than amiodarone [22, 23]. Two studies [25, 29] reported that hydrocortisone may be effective as a prophylactic treatment. However, these results are subject to much uncertainty due to methodological limitations.

International guidelines [12, 13] provide advice regarding the management of patients presenting acutely with AF, and/or patients with AF with haemodynamic instability. However, the evidence base and expert consensus on which these guidelines are based does not appear to include patients in the intensive care unit setting. Therefore, whilst they may be used to guide some general aspects of AF management in any patient, such as the recommendation to use cardioversion if the patient is acutely haemodynamically unstable, recommendations regarding pharmacological therapy and whether or not the patient should be anticoagulated, either short or long-term, may not apply to this specific patient population.

Comparative evidence for or against electrical cardioversion for patients in ICU with NOAF was not identified in our review. Electrical cardioversion should be considered in patients where AF is contributing to marked haemodynamic instability. NOAF often occurs alongside haemodynamic instability but is more likely to be a significant contributor where ventricular rates are very high or where there is underlying structural heart disease. As with other treatments, electrical cardioversion should be used alongside aggressive management of underlying AF drivers. Further procedural considerations are detailed elsewhere [58].

It is unclear whether to administer therapeutic anticoagulation in critically ill patients with NOAF for stroke prevention. Limited evidence suggests bleeding risk outweighs the increased risk of thromboembolism whilst in ICU [5, 39], but optimal timing of anticoagulation is unknown [34, 52]. Two review articles [51, 56] proposed a patient-centred approach to only administer anticoagulants in patients with high risk of arterial thromboembolic events. Notably, 64% of respondents of a UK wide survey [17] reported that they would not use anticoagulant therapy in critically ill patients with NOAF.

Included studies were consistent in recommending further research as optimal management strategies have yet to be determined. Findings from previous studies of NOAF in patients in ICU may have been affected by the heterogeneity of patients in a general ICU. Future studies of narrower populations may therefore be helpful to determine best practice in specific clinical scenarios.

Conclusions
Our systematic scoping review focusses on the comparative evidence for treatment of NOAF in patients in ICU. Interpretation of the evidence is limited due to study design flaws and important differences in definitions of NOAF, outcomes and treatment dose. Calcium channel blockers may result in more cardiovascular instability and slower rhythm control than amiodarone or beta blockers. More evidence is required about risk of bleeding and thromboembolism in the short and long term after NOAF onset. However, the little evidence available does not support therapeutic anticoagulation for NOAF whilst patients are critically ill. International guidelines regarding management of AF are largely based on studies and expert consensus that may not be applicable to this specific patient population. Given the significant morbidity and mortality associated with NOAF, adequately powered RCTs are needed to inform management of this common phenomenon. Consensus definitions of NOAF, and of treatment success will improve future studies.

Abbreviations
AF: Atrial fibrillation; CCB: Calcium channel blockers; ICU: Intensive care unit; NOAF: New onset atrial fibrillation; RCT: Randomised controlled trial.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13054-021-03686-5.

Additional file 1. Search strategy; detailed tables of studies by study design; critical appraisal; summary of reviews, surveys and opinion pieces; list of excluded studies.

Acknowledgements
We wish to thank the CAFE Study Team and the study oversight committee members Dr Andy Walden, Professor Ben O’Brien, and Ian & Cathy Taylor (public and patient representatives).
**Authors’ contributions**

PW, KR, DY, DH and PM developed study concept and design. KP provided expert review and advice on atrial fibrillation/arrhythmias. TP developed the search strategy. LD and LOB screened articles on title and abstract and full text. LD and JB extracted and reviewed the data and drafted the manuscript. MC contributed to the protocol, devised and supervised the scoping review, critically appraised the review evidence. PW, PM, MC, JD, KR, TP, LOB, LD and JB critically revised and approved the manuscript.

**Funding**

This project [Critical care Atrial Fibrillation Evaluation (CAFE)] was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (Project Number: 17/71/04).

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

Paul Mouncey, Kathryn Rowan, and David Harrison have received grants from National Institute for Health Research. Peter Watkinson worked part time for Sensyne Health and has received grant funding from National Institute for Health Research, Wellcome, and Sensyne Health outside the submitted work. No other authors had competing interests to declare.

**Author details**

1. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
2. Intensive Care National Audit and Research Centre (ICNARC), 24 High Holborn, London WC1V 6AZ, UK.
3. NIHR Biomedical Research Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford University Hospitals NHS Trust, Oxford, UK.
4. Cairns Library, University of Oxford Health Care Libraries, Oxford, UK.
5. Centre for Reviews and Dissemination, University of York, York, UK.
6. Cardiac Department, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Received: 5 May 2021 Accepted: 8 July 2021

Published online: 21 July 2021

**References**

1. Bedford J, Harford M, Petrinic T, Young JD, Watkinson PJ. Risk factors for new-onset atrial fibrillation on the general adult ICU: protocol for a systematic review. BMJ Open. 2018;8(9):e024640.
2. Artucio H, Pereira M. Cardiac arrhythmias in critically ill patients: epide-miologic study. Crit Care Med. 1990;18(12):1383–8.
3. Seguin P, Signouret T, Laviolette B, Branger M, Mallefont Y. Incidence and risk factors of atrial fibrillation in a surgical intensive care unit. Crit Care Med. 2004;32(3):722–6.
4. Knozter H, Mayr A, Ulmer H, Lederer W, Schoberbinger W, Mutz N, et al. Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. Intensive Care Med. 2000;26(7):908–14.
5. Kani S, Williamson DR, Yaguchi BM, Albert M, McIntyre L. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care. 2011;26(7):326.e1–8.
6. Yoshida T, Fujii T, Uchino S, Takinami M. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 1998;89(5):1052–9.
7. Guerlac A, Kane-Gill S, F Dasta J, Steinberg S, C Martin L, Cook C. Diltiazem versus amiodarone for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149–53.
8. Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bögelein D, et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Critical Care (Lond, Engl). 2010;14(5):R108.
9. Clayton B, Ball S, Read J, Waddy S. Risk of thromboembolism in patients developing critical illness-associated atrial fibrillation. Clin Med (Lond). 2018;18(4):282–7.
10. Waterslev M, Haase N, Hassager C, Bellbye-Cote EP, McIntyre WF, An Y, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review. Intensive Care Med. 2019;45(7):928–38.
11. Fernando SM, Matthew R, Hibbert B, Rochwerg B, Munshi L, Walkey AJ, et al. New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults-a multicenter retrospective cohort study. Crit Care. 2020;24(1):15.
12. Atrial fibrillation: management. National Institute for Health and Care Excellence, 2014.
13. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373–98.
14. Walkey AJ, Hogarth DK, Lip GYH. Optimizing atrial fibrillation management: from ICU and beyond. Chest. 2015;148(4):859–64.
15. Darwish OS, Strube S, Nguyen HM, Tanios MA. Challenges of anti-coagulation for atrial fibrillation in patients with severe sepsis. Ann Pharmacother. 2013;47(10):1266–71.
16. Moskwitz A, Chen KP, Cooper AZ, Chahin A, Ghassemi MM, Celi LA. Management of atrial fibrillation with rapid ventricular response in the intensive care unit: a secondary analysis of electronic health record data. Shock. 2017;48(4):436–40.
17. Chean CS, McAuley D, Gordon A, Welters ID. Current practice in the management of new-onset atrial fibrillation in critically ill patients: a UK-wide survey. Peep. 2017;5:e3716.
18. Bedford JP, Harford M, Petrinic T, Young JD, Watkinson PJ. Risk factors for new-onset atrial fibrillation on the general adult ICU: a systematic review. J Crit Care. 2019;53:169–75.
19. Yokota T, Uchino S, Yoshida T, Fuji T, Takinami M. Predictors for sus-tained new-onset atrial fibrillation in critically ill patients: a retrospective observational study. J Anesth. 2018;32(5):681–7.
20. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Bourton I, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;368:k4898.
21. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
22. Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 1998;89(5):1052–9.
23. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Goris R, Haumer M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149–53.
24. Gerlach A, Kane-Gill S, F Dasta J, Steinberg S, C Martin L, Cook C. Diltiazem versus amiodarone for new-onset atrial arrhythmias in non-cardiac post surgical patients: a cohort study 2008.
25. Launey Y, Lascob S, Asehoone K, Gaudriot B, Chassier C, Cinotti R, et al. Impact of low-dose hydrocortisone on the incidence of atrial fibrillation in patients with septic shock: a propensity score-inverse probability of treatment weighting cohort study. J Intensive Care Med. 2019;34(3):238–44.
26. Balik M, Kolinskyova I, Malý M, Waldau P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol. J Intensive Care. 2017;4:16–23.
27. Cho MS, Nam G-B, Kim YN, Hwang J, Kim M, Lee JH, et al. Abstract 20382: Comparison of Outcomes After Rhythm or Rate Control Strategy for the New-Onset Atrial Fibrillation in Critically Ill Sepsis Patients Managed in the Medical Intensive Care Unit. Circulation. 2017;136(Suppl_1):A20382-A.
28. Jaffer F, Anand S, Ajay-obe A, Parbtani R, Doraisswamy V, Malo J. Use of Amiodarone in Management of Atrial Tachyarrhythmias in Septic Shock. Chest. 2016;150(4):361A.

29. Kane S, Hanes S, editors. 946: Impact of hydrocortisone on atrial fibrillation in septic shock 2014.

30. Matsumoto Y, Shibata SC, Maeda A, Imada T, Okiitsu K, Fujino Y. Comparison of the short acting beta 1 blocker landiolol with amiodarone for pharmacological cardioversion for atrial fibrillation in intensive care unit patients. 2015 annual meeting of the international anesthesia research society; IARS 2015 Honolulu, HI United States. 2015;1203 SUPPL. 1:S109.

31. Brown M, Nassyos S, Chaney W, Plackett TP, Blackwell RH, Luchette F, et al. Impact and treatment success of new-onset atrial fibrillation with rapid ventricular rate development in the surgical intensive care unit. J Surg Res. 2018;229:66–75.

32. Miereu KD, Moranville MP, Park JJ, Lat I, Jennings HR, Lazar S, et al. A comparison of intravenous rate control agents for new onset atrial fibrillation with rapid ventricular rate. 32nd Annual Scientific Sessions of the Heart Rhythm Society. Heart Rhythm San Francisco, CA United States. 2011;8(SUPPL. 1):S216-S7.

33. Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study. Chest. 2016;149(1):74–83.

34. Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol. 2016;1(6):692–90.

35. Delle Karth G, Schillinger M, Geppert A, Haumer M, Gwechenberger M, Meyer B, et al. Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population. Wien Klin Wochenschr. 2005;117(3):92–7.

36. Hennersdorf MG, Perings SM, Zuhlke C, Heidland UE, Perings C, Heintzen MP, et al. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. Interventional Care Med. 2002;28(7):925–9.

37. Mayr A, Ritsch N, Knotzer H, Dunser M, Schoberbener W, Ulmer H, et al. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med. 2003;31(2):401–5.

38. Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth. 2016;30(5):891–4.

39. Slavik RS, de Lemos J, Gorman SK, Buchkowsky S. Patterns of practice for the acute management of new-onset atrial fibrillation in critically-ill intensive care unit patients. Crit Care Med. 2003;31(12):A137-A.

40. Slesewijk ME, Tulleken JE, Van Noord T, Lijtenberg JJ, Gitbers AR, Zijlstra JG. Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients—a clinical framework. Critical care (Lond, Engl). 2007;11(6):233.

41. Schwartz A, Broffain E, Kosyfman L, Klein M. Cardiac arrhythmias in a septic ICU population: a review. J Crit Care Med (Universitatea de Medicina si Farmacie din Targu-Mures). 2015;14(1):140–6.

42. Shapiro WA, Schulte K. An algorithm for the practical management of the new onset of atrial fibrillation in patients admitted to the ICU. JAACI. 2013;7(3):179–82.

43. Tran B. Atrial fibrillation in sepsis: should we worry? Relias Media. 2018.

44. Labbe V, Ederhy S, Fartoukh M, Cohen A. Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias? Arch Cardiovasc Dis. 2015;108(4):217–9.

45. Trohman RG. Atrial fibrillation in the critically ill: common sense for a common problem. Crit Care Med. 2008;36(5):1681–2.

46. Knowles PR, Press C. Anaesthesia for cardioversion. BJA Educ. 2017;17(5):166–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.